Fulvestrant, Palbociclib, Pertuzumab, and Trastuzumab
About
Membership operator: AND
Therapies: 4
Therapies
Fulvestrant (tx:ncit:C1379)
Palbociclib (tx:ncit:C49176)
Pertuzumab (tx:ncit:C38692)
Trastuzumab (tx:ncit:C1647)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | ER positive, HER2-positive | Invasive Breast Carcinoma | Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab | |
| FDA (2) | HER2-positive, PR positive | Invasive Breast Carcinoma | Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab |